haloperidol has been researched along with glucagon-like peptide 1 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daniels, JS; Days, EL; Gentry, PR; Jones, CK; Lindsley, CW; Locuson, CW; Morris, LC; Morrison, RD; Nance, KD; Niswender, CM; Niswender, KD; Thompson, AD; Weaver, CD | 1 |
1 other study(ies) available for haloperidol and glucagon-like peptide 1
| Article | Year |
|---|---|
Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM).
Topics: Allosteric Regulation; Animals; Catalepsy; Central Nervous System Agents; Drug Synergism; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Haloperidol; High-Throughput Screening Assays; Indoles; Insulin; Insulin Secretion; Islets of Langerhans; Male; Mice, Inbred C57BL; Microsomes, Liver; Peptides; Pyrrolidines; Receptors, Glucagon; Structure-Activity Relationship; Venoms | 2014 |